Glaucoma, Glaucoma; Drugs, Ocular Surface Disease
Conditions
Keywords
glaucoma, travoprost, prostaglandin without preservatives
Brief summary
Primary objective of this study is to study the efficacy of travoprost without preservatives in the treatment of glaucoma patients and to monitor the ocular surface.
Detailed description
This is a prospective study including patients visiting the outpatient glaucoma clinic of the University General Hospital of Alexandroupolis for their standard evaluation. Study population is already under treatment with a travoprost preparation without preservatives. They will be fully informed about the procedure and the purpose of the study and a written consent will be obtained. For every patient included in the study intraocular pressure will be measured using a Goldman applanation tonometer, according to the standard way of practice at our clinic. Also, Tear Break-Up-Time (BUT), conjunctival hyperemia grading and Schirmer testing will be used to assess the ocular surface state. Visual field tests and OCT RNFL measurements will also be obtained. The above measurements will be repeated 6 months after the initial examination.
Interventions
DIAGNOSTIC_TESTIntraocular pressure (IOP)
Measurement of intraocular pressure in both eyes of the study population using the Goldman applanation tonometer.
DIAGNOSTIC_TESTTear Break-up Time (TBUT)
TBUT will be calculated after instillation of a drop of fluorescein dye, by slit lamp biomicroscopy.
DIAGNOSTIC_TESTConjuctival Hyperemia
Conjunctival hyperemia will be assessed by slit lamp biomicroscopy using a validated grading system.
DIAGNOSTIC_TESTSchirmer Test
Schirmer test will be performed on both eyes to asses tear production.
DIAGNOSTIC_TESTVisual Fields and OCT RNFL
Visual field examination using a Humphrey perimeter and measurement of peripapillary retinal nerve fiber layer thickness with optical coherence tomography.
Sponsors
Democritus University of Thrace
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
35 Years to 90 Years
Inclusion criteria
* Patients with glaucoma treated with travoprost without preservatives.
Exclusion criteria
* Co-administration of another anti-glaucoma preparation with or without preservatives, Sjogren's syndrome, poor eyelid occlusion of any etiology.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Intraocular Pressure (IOP) | 6 months | Intraocular pressure measurement in both eyes using the Goldman applanation tonometer. |
| Ocular Surface Disease | 6 months | Tear breakup time (TBUT), conjuctival hyperemia scoring and Schirmer testing will be used to assess the ocular surface state of the study population. |
Countries
Greece
Outcome results
None listed